Core Viewpoint - Rosen Law Firm is reminding investors who purchased Perrigo Company plc securities between February 27, 2023, and November 4, 2025, of the January 16, 2026, deadline to become lead plaintiffs in a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Perrigo securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by January 16, 2026 [2]. - The lawsuit alleges that Perrigo made materially false and misleading statements regarding its infant formula business, which suffered from underinvestment and significant manufacturing deficiencies [4]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [3]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company, and has recovered hundreds of millions of dollars for investors [3]. - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [3].

Core Insights - Recent research has identified 410 genetic factors associated with gout, including 149 new factors, which supports the link between genetic predisposition and the over-expression of xanthine oxidase (XO) in gout and related diseases [3] - XORTX Therapeutics is focused on developing therapies that inhibit XO to treat gout and progressive kidney diseases, leveraging these genetic insights to guide treatment decisions [4][10] Company Updates - XORTX has appointed Krysta Davies Foss as a director, bringing over 25 years of experience in biotechnology and pharmaceutical strategy [5][6] - The company clarified details regarding a US$1.1 million Registered Direct Offering, correcting the number of pre-funded warrants issued [7] - XORTX is in the process of acquiring the Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems, with a closing date expected by January 13, 2026, pending ASX approval [8]

Core Viewpoint - The U.S. Food and Drug Administration (FDA) has declined to approve Outlook Therapeutics' drug for a specific type of eye disease, representing a significant setback in the company's ongoing efforts [1] Company Summary - Outlook Therapeutics has faced a prolonged effort to gain approval for its drug, which has now been rejected by the FDA [1]

Pill versions of GLP-1 drugs arrive in 2026, but analysts say Eli Lilly's lead in obesity and diabetes treatment should hold for years. ...

Core Viewpoint - The article highlights a pending securities class action lawsuit against Telix Pharmaceuticals Ltd. due to alleged misstatements regarding the company's therapeutic candidates and supply chain reliability, leading to significant investor losses [1][2][3]. Regulatory Setbacks - Telix faced multiple regulatory challenges, including an SEC subpoena and a Complete Response Letter (CRL) from the FDA, which resulted in a 21% decline in stock value following the final news [2][7]. - The SEC is investigating the company's disclosures related to the development of its prostate cancer therapeutic candidates, suggesting misleading statements about their advancement [7]. Allegations of Misrepresentation - The lawsuit claims that Telix and its executives overstated the developmental progress of its therapeutic candidates and misrepresented the reliability of its third-party supply chain and manufacturing partners [2][3]. - The complaint alleges that the SEC questioned the development disclosures, while the FDA rejected a Biologics License Application (BLA) due to deficiencies in Chemistry, Manufacturing, and Controls (CMC) [3][7]. Investor Impact - The cumulative effect of the regulatory disclosures reportedly caused significant financial damage to investors who purchased Telix ADSs during the Class Period from February 21, 2025, to August 28, 2025 [7]. - The firm Hagens Berman is actively advising investors who suffered substantial losses due to undisclosed flaws in the supply chain and therapeutic progress [5][6].

Core Viewpoint - The article highlights the offerings of the Biotech Analysis Central service, which provides in-depth analysis of pharmaceutical companies and investment opportunities in the biotech sector [1][2]. Group 1: Service Offerings - Biotech Analysis Central provides a library of over 600 biotech investing articles, a model portfolio featuring more than 10 small and mid-cap stocks, and live chat for investor engagement [2]. - The service is available for $49 per month, with a discounted annual plan at $399, representing a 33.50% savings for subscribers [1]. Group 2: Analyst Background - The author, Terry Chrisomalis, is a private investor with a background in Applied Science, focusing on generating long-term value in the healthcare sector [2]. - The analysis provided by Biotech Analysis Central aims to assist healthcare investors in making informed decisions through comprehensive reports and analyses [2].

Market Overview - U.S. stocks traded lower, with the Dow Jones index falling more than 100 points, down 0.28% to 48,229.87, NASDAQ down 0.26% to 23,359.33, and S&P 500 down 0.26% to 6,878.07 [1] - European shares were also lower, with the eurozone's STOXX 600 slipping 0.14%, Spain's IBEX 35 Index down 0.27%, London's FTSE 100 down 0.09%, and France's CAC 40 down 0.23% [6] - Asian markets closed mixed, with Hong Kong's Hang Seng Index falling 0.87%, China's Shanghai Composite gaining 0.09%, and India's BSE Sensex gaining 0.64% [7] Commodities - Oil traded up 0.1% to $58.02, while gold traded down 0.8% at $4,351.00, silver down 7.3% to $72.255, and copper fell 1.9% to $5.6710 [5] Company News - Anghami Inc. shares surged 50% to $3.7306 after reporting a year-over-year increase in H1 results [9] - Vanda Pharmaceuticals Inc. shares rose 32% to $9.28 following FDA approval of NEREUS for motion-induced vomiting prevention [9] - Intelligent Bio Solutions Inc. shares increased 102% to $8.27 after announcing a strategic manufacturing partnership with Syrma Johari MedTech [9] - Corcept Therapeutics Incorporated shares dropped 52% to $34.04 after receiving a Complete Response Letter from the FDA for Relacorilant [9] - FuelCell Energy, Inc. shares fell 10% to $7.18 after filing for an amended common stock offering [9] - SMX (Security Matters) Public Limited Company shares decreased 37% to $32.30 [9] Economic Indicators - U.S. initial jobless claims declined by 16,000 to 199,000, compared to market estimates of 220,000 [10] - U.S. crude oil inventories, excluding the Strategic Petroleum Reserve, dipped by 1.934 million barrels, marking the largest weekly decline since mid-November, against market estimates of a 0.9 million-barrel fall [2][10]

Core Viewpoint - The FDA has determined that there is insufficient evidence of effectiveness for relacorilant in treating patients with Cushing syndrome and hypertension, resulting in a significant decline in the stock price [1] Group 1 - The FDA's decision highlights concerns regarding the efficacy of relacorilant, which may impact its market potential and investor confidence [1] - The announcement has led to a sharp decrease in the stock value, indicating a negative market reaction to the FDA's findings [1]

Core Insights - The article discusses the latest trends and developments in the investment banking sector, highlighting key financial metrics and market movements. Group 1: Industry Trends - The investment banking industry is experiencing a significant shift due to increased regulatory scrutiny and changing market dynamics [1] - There is a growing emphasis on technology integration within investment banking firms to enhance operational efficiency and client service [1] Group 2: Company Performance - Major investment banks reported a mixed performance in their latest quarterly earnings, with some firms showing a revenue increase of 15% year-over-year while others faced declines [1] - The overall market sentiment remains cautious, with analysts predicting potential volatility in the coming quarters due to geopolitical tensions and economic uncertainties [1]

Key Points Great dividend payers can support and raise their payouts through the years. VICI Properties is a leading REIT with a vast portfolio of experience-oriented properties. Bristol Myers Squibb is a top pharmaceutical business with a vast portfolio of profitable drugs. 10 stocks we like better than Vici Properties › Adding dividend stocks to your portfolio can provide a steady source of income and help buffer portfolio losses during market downturns. However, it's important to carefully re ...